RELATED STUDY

Key Findings: 

Type of Study: 

Study Result:  Inconclusive

Research Location(s): 

Year of Pub: 


Cannabinoids Studied: 

Chemotype: 

Terpenes Studied: 

Receptors Studied: 

Ligands Studied: 

DOSING DETAILS   

Study Dosing Objective:  Effective Dose, Safety Profile,

Established Protocol:  Effective dose with adverse effects

Route of Administration: 

Cannabinoid Ratio:  (CBD : Pharma CBD)   0 : 0    

Dosage Form:  cannabidiol or Epidiolex

Maximum Dose:  20 mg/kg body mass/d

Adverse Events:  CBD is not associated with major safety risks: changes in somnolence, decreased appetite, diarrhea, hormone changes, decreased fertility, and hepatic impairment at higher dosing.




Citation: